ACE Gene

ACE Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ACE Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ACE</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Angiotensin-Converting Enzyme</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>17q23.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1636</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000159640</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P12821</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>106180</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Metalloprotease (M2 family)</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Human</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), Cardiovascular Disease, Hypertension, SARS-CoV-2</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Captopril</td>
<td>Inhibitor</td>
</tr>
<tr>
<td class="label">Lisinopril</td>
<td>Inhibitor</td>
</tr>
<tr>
<td class="label">Enalapril</td>
<td>Inhibitor</td>
</tr>
<tr>
<td class="label">Ramipril</td>
<td>Inhibitor</td>
</tr>
<tr>
<td class="label">Perindopril</td>
<td>Inhibitor</td>
</tr>
</table>

ACE Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ACE Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ACE</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Angiotensin-Converting Enzyme</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>17q23.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1636</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000159640</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P12821</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>106180</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Metalloprotease (M2 family)</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Human</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), Cardiovascular Disease, Hypertension, SARS-CoV-2</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Captopril</td>
<td>Inhibitor</td>
</tr>
<tr>
<td class="label">Lisinopril</td>
<td>Inhibitor</td>
</tr>
<tr>
<td class="label">Enalapril</td>
<td>Inhibitor</td>
</tr>
<tr>
<td class="label">Ramipril</td>
<td>Inhibitor</td>
</tr>
<tr>
<td class="label">Perindopril</td>
<td>Inhibitor</td>
</tr>
</table>

Ace Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Pathway Diagram

Knowledge graph relationships for ACE (311 total edges in KG)

Overview

The ACE gene encodes angiotensin-converting enzyme (ACE), a key component of the renin-angiotensin system (RAS) that regulates blood pressure, fluid balance, and electrolyte homeostasis. ACE is a zinc-dependent metalloprotease that converts angiotensin I (Ang I) to the potent vasoconstrictor angiotensin II (Ang II). Beyond its cardiovascular roles, ACE has significant implications for neurodegenerative diseases, particularly Alzheimer's disease, where ACE activity influences [Aβ](/proteins/amyloid-beta) metabolism and neuroinflammation. The ACE I/D polymorphism (insertion/deletion) is one of the most studied genetic variants in relation to AD risk and cardiovascular disease.

Molecular Function

ACE is a dipeptidyl carboxypeptidase with two homologous catalytic domains (N- and C-domains):

• Angiotensin conversion: Ang I → Ang II (vasoconstrictor)
• Bradykinin degradation: Inactivates bradykinin (vasodilator)
• Substrate specificity: N-domain preferentially cleaves Ang I, bradykinin; C-domain processes Ang I
• Zinc binding: Active site contains Zn2+ coordinated by three histidine residues
• Somatic ACE: Contains two catalytic domains; germinal ACE has one domain

• Two isoforms: Somatic ACE (two domains) and testicular/germinal ACE (one domain)
• Membrane-bound: Type I transmembrane protein with extracellular domain
• Soluble form: Can be shed from membrane
• ACE2: Related enzyme that converts Ang II to Ang(1-7)

Expression Pattern

Tissue Distribution

• Highest: Lung, kidney (proximal tubules)
• High: Testis, heart, brain (cerebral [cortex](/brain-regions/cortex), hippocampus)
• Moderate: Vascular endothelium, adrenal gland, liver
• Low: Most other tissues

Brain Expression

• [Neurons](/entities/neurons): Cortical neurons, hippocampal neurons
• Glia: [Astrocytes](/entities/astrocytes), [microglia](/entities/microglia)
• Vasculature: Cerebral blood vessels
• Choroid plexus: High expression

Role in Neurodegenerative Diseases

Alzheimer's Disease

ACE plays complex roles in AD pathogenesis:

• Aβ metabolism: ACE can degrade Aβ peptides, particularly Aβ1-40
• Angiotensin II effects: Ang II promotes neuroinflammation and oxidative stress
• Cerebral blood flow: ACE affects cerebrovascular function
• Genetic association: ACE I/D polymorphism affects AD risk
• Therapeutic implications: ACE inhibitors may reduce AD risk

Parkinson's Disease

• Neuroinflammation: ACE modulates neuroinflammatory responses
• Dopaminergic neurons: ACE affects survival of dopaminergic neurons
• L-dopa response: ACE activity may affect treatment response
• Gene variants: ACE polymorphisms linked to PD risk

Stroke and Vascular Dementia

• Blood pressure: ACE regulates cerebral perfusion
• Stroke risk: ACE inhibitors reduce stroke risk
• White matter lesions: ACE affects small vessel disease

SARS-CoV-2/COVID-19

• Viral entry: ACE2 is the viral receptor; ACE/ACE2 balance important
• Neurological symptoms: COVID-19 can affect the brain
• Research: ACE inhibitors may have protective effects

Therapeutic Implications

Current Therapeutics

Alzheimer's Disease

• Observational studies: ACE inhibitor use associated with reduced AD risk
• Clinical trials: Mixed results; some benefit seen
• Mechanisms: Reduced Ang II, enhanced bradykinin, decreased inflammation
• Combination therapy: ACEi + other approaches under investigation

Research Directions

• Brain-penetrant ACE inhibitors: Develop CNS-selective compounds
• ACE modulators: Selective N-domain or C-domain inhibitors
• ACE2 activators: Enhance protective ACE2 signaling
• Gene therapy: AAV-delivered ACE variants

Animal Models

ACE Knockout Mice

• Blood pressure: Hypotension due to low Ang II
• Bradykinin: Accumulation of bradykinin
• Kidney: Renal developmental abnormalities
• Fertility: Male infertility (germinal ACE)

Transgenic Models

• Neuron-specific ACE overexpression
• AD models with ACE manipulation
• Cardiovascular disease models

Research Directions

Background

The study of Ace Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Data

Angiotensin-converting enzyme (ACE) expression in the human brain has been characterized through the Allen Brain Atlas:

• Primary Expression: ACE is expressed in [endothelial cells](/cell-types/endothelial-cells) of blood vessels throughout the brain, with lower expression in neurons
• Regional Distribution: Highest expression in brain regions with dense vascular networks, including the hippocampus and cerebral cortex
• Cellular Localization: Primarily localized to vascular endothelial cells; expression in microglia is inducible during inflammation
• Disease Relevance: ACE expression in the brain renin-angiotensin system is relevant to hypertension-related cerebrovascular damage and vascular contributions to AD

Related Resources

• [Allen Brain Atlas Human Brain Atlas](https://human.brain-map.org/)
• [Allen Brain Atlas Gene Expression](https://mouse.brain-map.org/gene/index)

External Links

• [NCBI Gene: ACE](https://www.ncbi.nlm.nih.gov/gene/1636)
• [UniProt: ACE](https://www.uniprot.org/uniprot/P12821)
• [Human Protein Atlas: ACE](https://www.proteinatlas.org/ENSG00000159640-ACE)
• [IUPHAR Database: ACE](https://www.guidetopharmacology.org/GRID/IUPHAR/ACE.jsp)
• [PharmGKB: ACE](https://www.pharmgkb.org/gene/PA26239)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation](/hypothesis/h-fb56c8a0) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: SDC1
• [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: LOX/LOXL1-4
• [Astroglial Gap Junction Coordination via Connexin-43 Phosphorylation Modulation](/hypothesis/h-3a901ec3) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: GJA1
• [Pericyte Contractility Reset via Selective PDGFR-β Agonism](/hypothesis/h-73e4340b) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: PDGFRB
• [Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modulation](/hypothesis/h-9eae33ba) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: KCNK2
• [Osmotic Gradient Restoration via Selective AQP1 Enhancement in Choroid Plexus](/hypothesis/h-0dea0ed5) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: AQP1

Related Analyses:

• [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) &#x1f504;
• [Extracellular vesicle biomarkers for early AD detection](/analysis/SDA-2026-04-02-gap-ev-ad-biomarkers) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving ACE Gene discovered through SciDEX knowledge graph analysis: